Live birth after letrozole as an adjunct to follicle-stimulating hormone versus follicle-stimulating hormone alone for ovarian stimulation in in vitro fertilisation cycles—study protocol for a randomised controlled trial

Wei Guo¹,²,³,⁴, Hang Wun Raymond Li⁵, Zi Yang¹,²,³,⁴, Lin Zeng⁶, Rui Yang¹,²,³,⁴, Jie Qiao¹,²,³,⁴, Rong Li¹,²,³,⁴* and Ernest Hung Yu Ng⁵

Abstract

Introduction: In vitro fertilisation (IVF) is an effective infertility treatment but the live birth rate remains unsatisfactory. Ovarian stimulation by follicle-stimulating hormone (FSH) is routinely used in IVF and the resulting high serum estradiol levels may impair oocyte/embryo quality and endometrial receptivity. Letrozole, an aromatase inhibitor, can reduce serum estradiol levels following ovarian stimulation. We aim to test the hypothesis that co-treatment with letrozole reduces supraphysiological serum estradiol levels and improves endometrial receptivity, leading to a higher live birth rate of IVF. We are conducting a randomised controlled trial (RCT) to evaluate whether letrozole as an adjunct to FSH in IVF is superior to FSH alone in the live birth rate of fresh embryo transfer.

Methods/design: This is an open-label randomised controlled superiority trial being performed in two assisted reproduction centres in China. Infertile women who have antral follicle count (AFC) before ovarian stimulation or on day 5 of ovarian stimulation ≥15 are randomly allocated in a 1:1 ratio to receive either letrozole and FSH or FSH alone in a GnRH antagonist protocol. Recruited women follow the standard operating procedures of the two centres. The primary outcome is the live birth rate of the fresh embryo transfer. Stimulation parameters, maternal side effects and obstetric and perinatal complications are secondary outcomes. The planned sample size is 900, i.e. 450 per group.

Discussion: The present study is the first multicentre randomised study to compare the live birth rate of the fresh embryo transfer following ovarian stimulation by letrozole and FSH versus FSH alone in women with anticipated high ovarian responses.
**Background**

Despite improvements in ovarian stimulation regimens and laboratory techniques, the live birth rate of in vitro fertilisation (IVF) remains unsatisfactory [1]. Ovarian stimulation is used in the great majority of IVF cycles and may lead to high serum estradiol (E2) levels with adverse effects on oocyte/embryo quality and endometrial receptivity [2–6].

High serum E2 levels have been implicated in reducing oocyte quality and increasing embryo aneuploidy rates [4–7]. The impact of supraphysiological E2 levels on endometrial receptivity includes disruption of endometrial gene expression [8], cytokine profiles [9] and histological markers of endometrial receptivity [10, 11]. High serum E2 level during ovarian stimulation is associated with an increased risk of small for gestational age and preeclampsia in singleton pregnancies after IVF [12].

Letrozole, a third-generation aromatase inhibitor, reduces the intraovarian aromatisation of androgens to oestrogens. It is now the first-line drug treatment for ovulation induction in women with polycystic ovary syndrome (PCOS) [13] and is routinely used as a co-treatment during ovarian stimulation in women with hormone-sensitive cancers such as breast cancer to reduce the risk of recurrence associated with high serum E2 levels during ovarian stimulation [14]. Peak serum E2 levels were significantly lower in the letrozole cohort [15–17].

Letrozole has been used for endometrial preparation in frozen embryo transfer (FET) in women both with anovulation caused by PCOS and with regular cycles. Retrospective studies [18–20] showed that the ongoing pregnancy rate or live birth rate of FET in letrozole-induced cycles was significantly higher than that in hormonal cycles of women with polycystic ovary syndrome or ovulation disorders. A large retrospective cohort study [21] reported the pregnancy outcomes of 110,722 FET cycles replacing a single embryo in letrozole, natural or hormonal cycles. The rates of clinical pregnancy, ongoing clinical pregnancy and live birth were significantly higher, while the rate of miscarriage was significantly lower in the letrozole group compared with the natural and hormone replacement therapy (HRT) groups.

The above studies indicate that adding letrozole to ovarian stimulation may improve endometrial receptivity by reducing supraphysiological serum E2 levels and have a direct effect on endometrial receptivity. By combining sufficient FSH stimulation to produce adequate numbers of oocytes, with a simple oral adjuvant therapy aimed at preventing excessive estradiol levels, the resultant stimulation protocol may provide a ‘best of both worlds’ solution, in which adequate numbers of oocytes are obtained, but not at the cost of detrimental impacts on oocyte, embryo or endometrial quality.

The aim of this multicentre randomised controlled trial is to test the hypothesis that co-treatment with letrozole leads to a higher live birth rate of fresh embryo transfer.

**Study setting**

This is an open-label randomised controlled superiority trial being performed in the Department of Obstetrics & Gynaecology, The University of Hong Kong, and the Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital. Written informed consent was obtained from all participants before participation in the study.

**Methods/design**

**Study design**

Eligible women will be given information about the study during their first consultation. All recruited women provided written informed consent before participation. The trial was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW16-014) and the Ethics Committee of Peking University Third Hospital (2016sz-066). The study was registered on Clinicaltrials.gov (NCT02912988).

The enrollment, interventions and evaluation during the study process are shown in Table 1. Figure 1 indicates a flowchart showing registration, allocation, intervention and follow-up of participants.

**Recruitment**

Infertile women undergoing IVF treatment at the Department of Obstetrics & Gynaecology, the University of Hong Kong, and the Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, will be screened for eligibility. Eligible women will be counselled about the trial on the first day attending the centres for ovarian stimulation. Written informed consent will be obtained before treatment.
Eligibility criteria

**Inclusion criteria**

- Women less than 42 years of age
- Having a medical indication for IVF treatment
- Total antral follicle count (AFC) on pelvic scanning before ovarian stimulation or on day 5 of stimulation ≥15
- Written informed consent obtained

**Exclusion criteria**

- Women using donor oocytes
- Women undergoing preimplantation genetic testing
- Women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram
- Women with hydrosalpinges shown on scanning and not corrected
- Having previously documented poor response, i.e. ≤3 oocytes to ovarian stimulation using at least FSH 225 IU daily

Randomisation and allocation concealment

Recruited women will be randomly allocated in a 1:1 ratio to the letrozole group or the control group according...
to a computer-generated randomisation list put in opaque sealed envelopes which are open consecutively for eligible participants after screening. Both investigators and participants are aware of the allocation of the intervention. The biostatistician performing the data analysis will be blinded to the group allocation.

**Interventions**

A gonadotropin-releasing hormone (GnRH) antagonist regimen is used. Human menopausal gonadotropin (HMG; Menopur, Ferring Pharmaceuticals, Saint-Preix, Switzerland) or recombinant human follicle-stimulating hormone (FSH; Gonal-F, Merck Serono, Geneva, Switzerland) is administered at a dose of 150 to 225 IU per day based on body mass index and previous ovarian response on day 2–4 of the menstrual cycle, at the discretion of the physicians. Transvaginal scanning, serum luteinizing hormone (LH), oestrogen (E2) and progesterone (P4) will be performed regularly to monitor ovarian response. HMG or FSH doses will be adjusted according to ovarian responses.

GnRH antagonist 0.25 mg (Cetrotide, Merck Serono, Darmstadt, Germany, or Orgalutran, Merck Sharp & Dohme Ltd.) is started from day 5 of stimulation until the day of the trigger. When three or more follicles reach a diameter ≥ 17 mm, 250 μg of rhCG (Ovidrel; Serono, Aubonne, Germany) or triptorelin 0.2 mg (Diphereline, Ipsen Beaufour) is to be given for final maturation. Oocyte retrieval is performed around 36 h after the trigger.

In the letrozole group, letrozole (Letroz, Sun Pharmaceuticals, Mumbai, India) 2.5 mg daily is started from day 5 of stimulation until the day before the trigger. The control group will not receive letrozole.

When the serum estradiol level on the day of hCG administration or before the day was ≥20,000 pmol/L, 0.2 mg of triptorelin (Ferring International Center, Saint-Prex, Switzerland) will be given for agonist trigger. When the serum estradiol level on the day of hCG administration or before the day was 15,000–20,000 pmol/L, 0.2 mg of triptorelin (Ferring International Center, Saint-Prex, Switzerland) and 2000 IU of hCG (Livzon,
Zhuhai, China) or 125 mg of recombinant hCG (Ovidrel; Merck Serono) will be given.

The freeze-all strategy to prevent ovarian hyperstimulation syndrome (OHSS) is advised in women with (1) E2 on HCG day ≥15,000 pmol/L, (2) retrieved oocyte number ≥20, and (3) E2 on HCG day ≥10,000 pmol/L and retrieved oocyte number ≥15.

**Assessment of fertilisation and embryo culture**
Oocytes are cultured in Human Tubal Fluid medium and incubated in a humidified 37 °C incubator with 5% CO2, after oocyte retrieval immediately. The fertilisation method will be selected according to the parameters of the semen analysis.

Fertilisation will be considered normal when two pronuclei are present between 16 and 18 h after conventional insemination or intracytoplasmic sperm injection (ICSI). All zygotes will be cultured in a cleavage medium (G-1plus, Vitrolife, USA) for further 48–52 h after fertilisation. Cleavage stage embryos will be assessed according to the developmental stage and degree of cytoplasmic fragmentation.

**Embryo transfer and luteal support**
Fresh embryo transfer or elective freezing of all embryos will be decided by physicians according to the conditions of women. All embryos will be cryopreserved without fresh transfer when the women are at risk of OHSS, have elevated serum progesterone level on the trigger day (>1.5 ng/L or >5 nmol/L) or had endometrial polyps or fluid in the uterine cavity. To reduce the risk of multiple pregnancies, up to two embryos will be transferred on day 2/3 and one blastocyst will be replaced on day 5. Excess cleavage stage embryos will be vitrified or further cultured to the blastocyst stage while excess blastocyst will be vitrified accordingly.

In women with fresh embryo transfer, the luteal phase is supported with vaginal progesterone gel (Crinone, Merck Serono) at a dose of 90 mg daily or oral progesterone (Duphaston, Abbott) at a dose of 10 mg three times daily from the day of oocyte retrieval until the day of serum or urine hCG test.

**Follow-up**
Transvaginal ultrasonography will be performed 2 weeks after a positive serum or urine pregnancy test to confirm intrauterine pregnancy. Scanning will be repeated later to confirm ongoing pregnancy, which is defined as a viable pregnancy with a foetal heartbeat at 10–12 weeks. Information regarding the outcome of the pregnancy and obstetrical and perinatal complications will be obtained through a review of obstetrical medical records and neonatal medical records. The live birth is defined by the live foetus in the uterine after 20 weeks of gestation.

We will collect the following information within 6 weeks after delivery, including antenatal information (pregnancy complications and foetal information), delivery information (gestational age, mode of delivery, placental weight and birth complications) and newborn information (foetal sex, birth weight and birth defects).

**Measurement of outcomes**

**Primary outcome**
The primary outcome is the live birth rate after 20 weeks of gestation following the fresh transfer.

**Secondary outcomes**
Secondary outcomes include pregnancy outcomes, maternal safety and obstetric and perinatal complications. Detailed information is provided in Table 2. Maternal safety is an important part of the secondary outcomes. The incidence of OHSS is the key indicator of maternal safety and is classified as mild, moderate or severe according to the RCOG guideline.

**Safety reporting**
Adverse events (AE) are defined as any undesirable experience occurring to a subject during the trial. A serious adverse event (SAE) is any untoward medical event that results in death, is life-threatening (at the time of the event), requires hospitalisation or prolongation of existing inpatients’ hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect and is a new event of the trial likely to affect the safety of the subjects, such as an unexpected outcome of an adverse reaction.

SAE in this study includes moderate/severe OHSS, intraperitoneal haemorrhage or ovarian torsion after oocyte retrieval, ectopic pregnancy, severe preeclampsia, pregnancy complications leading to hospitalisation, stillbirth, birth defects and other serious medical events judged by researchers to meet the criteria of SAE.

**Statistical analysis**

**Sample size calculation**
The primary hypothesis of this trial is that the letrozole group will increase the live birth rate when compared with the control group. This treatment will be considered effective if the proportion of women having a live birth is increased by 10% in absolute terms. With an 80% power and a one-sided 2.5% level of statistical significance, we will need to recruit 752 women (376 in each arm) to show an absolute difference of 10% from 35 to 45% between control and letrozole groups. Taking consideration of the dropout rate as 20% (such as cancellation of fresh embryo transfer because of high...
Table 2 Secondary outcomes and related definition

| Secondary outcomes | Definition |
|--------------------|-----------|
| **Clinical and laboratory outcomes** | |
| Total amount of FSH | Total amount of FSH used for ovarian stimulation |
| Number of follicles > 12 mm | The number of follicles > 12 mm measured by transvaginal ultrasound on the day of the trigger or the day before |
| Number of oocytes obtained | Number of oocytes obtained during oocyte retrieval |
| Number of embryos obtained | Number and quality of embryos obtained |
| Proportion of good-quality embryos | Embryos with 4 cells and < 25% fragmentation on day 2 or with ≥ 6 cells and ≤ 10% fragmentation on day 3, the proportion of oocytes resulting in top quality day 2 (or day 3) embryos according to validated morphological criteria |
| Oocyte fertilisation rate | The number of zygotes with 2PN over the number of mature oocytes for ICSI or over the number of oocytes for conventional insemination |
| Endometrial thickness | Endometrial thickness measured by transvaginal ultrasound on the day of the trigger or the day before |
| Serum E2 level | Serum E2 level on the day of the trigger or the day before |
| Serum P level | Serum P level on the day of the trigger or the day before |
| Serum testosterone level | Serum testosterone level on the day of the trigger or the day before |
| Follicular fluid E2 level | E2 level in the follicular fluid |
| Follicular fluid testosterone level | Testosterone level in the follicular fluid |
| Follicular fluid inhibin B level | Inhibin B level in the follicular fluid |
| Follicular fluid AMH level | AMH level in the follicular fluid |
| **Pregnancy outcomes** | |
| Miscarriage | Spontaneous loss of an intrauterine pregnancy before 20 completed weeks of gestational age |
| Clinical pregnancy | Presence of one or more intrauterine gestational sacs at 6 weeks of gestation |
| Ongoing pregnancy | Presence of one or more gestational sacs and foetal heartbeat after 12 weeks of gestation |
| **Maternal safety outcomes** | |
| OHSS | It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory haemodynamic, and metabolic complications. Diagnosed by ultrasound, blood testing and physical examination according to the RCOG Guideline |
| Ectopic pregnancy | A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualisation or histopathology |
| **Obstetric and perinatal complications** | |
| Hypertensive disorders of pregnancy | Including pregnancy-induced hypertension, preeclampsia and eclampsia |
| Antepartum haemorrhage | Including placenta previa, placenta accreta and unexplained |
| Multiple pregnancies | Pregnancy with more than one foetus |
| Birth weight | Including low birth weight (weight < 2500 g at birth), very low birth weight (< 1500 g at birth), high birth weight (> 4000 g at birth) and very high birth weight (> 4500 g at birth) |
| Small for gestational age | Birth weight less than the 10th centile for the sex-specific birth weight for a given gestational age reference |
| Preterm delivery | Birth of a foetus delivered after 28 and before 37 completed weeks of gestational age |
| Congenital anomaly | Structural or functional disorders that occur during intrauterine life and can be identified prenatally, at birth or later in life, including trisomy 21 syndrome, neural tube defect, congenital heart disease, cleft lip, excessive numbers of fingers or toes and hydrocephalus |
| Perinatal mortality | Foetal or neonatal death occurring during late pregnancy (at 28 completed weeks of gestational age and later), during childbirth, or up to seven completed days after birth |
risk of OHSS), each group will include 450 women (a total of 900 women).

**Statistical analysis**
The result will be analysed according to the intention-to-treat (ITT) principle. Per-protocol (PP) analysis will also be conducted as a sensitivity analysis. Baseline characteristics will be described by descriptive analysis and the balance among groups or subgroups will be assessed by analysis for different kinds of data. For continuous variables, the normality distribution will be estimated by using frequency histograms and the Kolmogorov-Smirnov test initially. If the continuous variables are normally distributed, they will be presented as means with standard deviations (SDs). If the continuous variables are non-normally distributed, their medians and interquartile ranges (IQRs) will be reported. For categorical variables, we will present the proportion between each group. In addition, the recruitment number, those participants lost to follow-up, protocol violations and other relevant data will also be reported. A comparison between groups will be performed using the independent sample t-test, Mann-Whitney U test for continuous variables or Pearson chi-square test/Fisher’s exact test for categorical variables as appropriate. The primary outcome will be compared using Pearson’s chi-square test or Fisher’s exact test as appropriate. Categorical secondary outcomes will be compared between two groups using a similar approach as the primary outcome. Student’s t-test or Wilcoxon test will be used as appropriate for continuous secondary outcomes, such as birth weight, etc. The relative risks (RR) and absolute rate differences (ARD) and their 95% confidence interval (CI) between the two groups will be calculated. And the 99% CI of the ARDs will be used to evaluate if the letrozole group is superior to the control group. Multiple variable logistic regression models will be used to assess the treatment effect adjusting for other potential confounding variables that are unbalanced in the baseline.

Missing data will be treated as missing at random and will be imputed using the last observation carried forward (LOCF) method. For the missing values, a sensitivity analysis will be done under the hypothesis of the worst and the best outcomes for each missing individual. Therefore, all secondary outcomes will be considered exploratory. All statistical analyses will be done using the statistical package SPSS (version 26.0, released 2019, IBM corp., Armonk, NY, USA). Statistical significance is defined as $p < 0.05$ with two-sided testing.

**Discussion**
Letrozole is usually used for ovulation induction in anovulatory women and ovarian stimulation and intrauterine insemination for treatment of unexplained infertility. It is now routinely used in women with breast cancer undergoing fertility treatment in order to prevent recurrent breast cancer as a result of supraphysiological estradiol level following ovarian stimulation [14]. Its use in poor responders and normal responders in IVF may reduce the total gonadotropin dose required for ovarian stimulation without increasing the pregnancy rate [24–26]. The hypothesis of the present study is that adding letrozole to gonadotropin in the ovarian stimulation protocol in high responder patients can improve the live birth rate of women with anticipated high ovarian response in IVF. The present study is the first randomised study which provides high-quality evidence about the efficacy of co-administration of letrozole in high ovarian responders and IVF cycles and may open new insights into the clinical management of this group of women.

The strengths of the present study include randomisation, a large adequate sample size to show a 10% absolute difference in the live birth rate between the intervention and control groups and the live birth rate as the primary outcome, which is the most important clinical outcome in fertility treatment studies. Most women prefer to choose embryo transfer in the fresh cycle instead of transfer in frozen cycles because of time constrain, economic reasons and psychological factors, so the use of letrozole during ovarian stimulation for IVF producing a good number of oocytes with physiological levels of estradiol may reduce the adverse impact on endometrial receptivity and increase the success rate of the IVF treatment. To increase the external validity of this trial, we did not limit embryo transfer to day 3 or day 5 only and the results of day 3 and day 5 transfer will be separately analysed. The timing of embryo transfer is unlikely to influence the results because of randomisation in the study.

The limitation is the lack of cumulative live birth rate of the stimulated IVF cycle.

**Trial status and peer review**
The first participant was recruited in March 2018, and it is anticipated the recruitment will end by the end of April 2022. The follow-up is ongoing and the expected data collection will be completed in February 2023. This trial protocol is version 2.0, 20/11/2017. At the time of the manuscript preparation, we have recruited 890 women and the recruitment is currently ongoing. This study is externally peer-reviewed and does not receive any external funding.

**Abbreviations**
AE: Adverse events; AFC: Antral follicle count; E2: Estradiol; FET: Frozen embryo transfer; FSH: Follicle-stimulating hormone; GnRH: Gonadotropin-releasing hormone; hCG: Human chorionic gonadotropin; HMG: Human menopausal gonadotropin; HRT: Hormone replacement therapy; IVF: In vitro fertilisation; ICSI: Intracytoplasmic sperm injection; LH: Luteinizing hormone; OHSS: Ovarian hyperstimulation syndrome; P4: Progesterone;
PCOS: Polycystic ovary syndrome; RCT: Randomised controlled trial; SAE: Serious adverse event

Acknowledgements
We gratefully acknowledge all the participants enrolled in this trial. The enrolment, interventions and evaluation during the study process are shown in Table 1. Secondary outcomes are in Table 2. Figure 1 indicates the flowchart of registration, allocation, intervention and follow-up of participants.

Dissemination and ethics
The trial was approved by the Science Research Ethics Committee of Peking University Third Hospital (2016Z-066) and the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW16-014) and was registered on Clinicaltrials.gov (NCT02912988). The researchers will permit trial-related monitoring, audits, regulatory inspections and providing direct access to source data and documents. There are no additional data available in this study protocol.

The public and patient involvement
This research is done without patient or public involvement. Neither patients nor the public are involved in the development of the research question, study design or implementation of this trial. Patients are not invited to develop patient-relevant outcomes or interpret the results, as well as the writing or editing of the final manuscript for readability or accuracy.

Authors’ contributions
EH Ng and RL conceived the study idea. EH Ng, RL, WG and HWR L participated in the design of the study and drafting of the manuscript. EH Ng, RL, WG, HWR L, ZY, RY and JQ participate in the recruitment of participants and the assessment of clinical outcomes. EH Ng and JQ supervised patient diagnosis and recruitment in each study centre. WG, HWR L, RY and LZ coordinate data collection and will perform data analysis. The manuscript was drafted by WG, RL and EH Ng. All authors critically reviewed the article and approved the final manuscript.

Funding
This study was supported by the National Key Research and Development Program of China (grant no. 2021YFC2006001, 2021YFC2006005), the Beijing-Tianjin-Hebei Basic Research Cooperation Project (19JCZJD05000). The study funders had no role in the study design, implementation, analysis, manuscript preparation or decision to submit this article for publication.

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Declaration
Competing interests
The authors declare that they have no competing interests.

Author details
1Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No.49 North Huayan Road, Haidian District, Beijing 100191, China. 2National Clinical Research Centre for Obstetrics and Gynecology, Beijing 100191, China. 3Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing 100191, China. 4Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing 100191, China. 5Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, Special Administrative Region, China. 6Research Centre of Clinical Epidemiology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.

Received: 30 January 2022 Accepted: 18 March 2022
Published online: 01 April 2022

References
1. Ferraretti AP, Goossens V, de Mouzon J, Bhattacharya S, Castilla JA, Korsak V, et al. Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE. Hum Reprod. 2012;27(9):2571–84. https://doi.org/10.1093/humrep/des255.
2. Ng EH. Adverse effects of excessive ovarian response on the pregnancy rate of in vitro fertilization treatment. Gynecol Endocrinol. 2009;25(1):2–7. https://doi.org/10.1080/095135908021992637.
3. Silva-Martins R, Helio Oliani A, Yaz Oliani D, Martínez de Oliveira J. The predictive value of serial serum estradiol and serial endometrial volume on endometrial receptivity on assisted reproductive technology cycles. BMC Pregnancy Childbirth. 2021;21(1):184. https://doi.org/10.1186/s12884-021-03672-1.
4. Macklon NS, Stouffer RL, Guidice LC, Fauser BC. The science behind 25 years of in vitro stimulation for in vitro fertilization. Endocr Rev. 2006;27(2):172–207. https://doi.org/10.1210/er.2005-0015.
5. Rubio C, Mercader A, Alama P, Lizan C, Rodrigo L, Labarta E, et al. Prospective cohort study in high responder oocyte donors using two hormonal stimulation protocols: impact on embryo aneuploidy and development. Hum Reprod. 2010;25(9):2290–7. https://doi.org/10.1093/humrep/ded174.
6. Santos MA, Kuikj EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction. 2010;139(1):23–34. https://doi.org/10.1530/REP-09-0187.
7. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod. 2007;22(4):980–8. https://doi.org/10.1093/humrep/deh484.
8. Horcajadas JA, Minguez P, Dopazo J, Esteban FJ, Dominguez F, Guidice LC, et al. Controlled ovarian stimulation induces a functional genomic delay of the endometrium with potential clinical implications. J Clin Endocrinol Metab. 2008;93(11):4500–10. https://doi.org/10.1210/jc.2008-0588.
9. Boomstra CM, Kavelaars A, Eijkemans MJ, Fauser BC, Heijn J, Macklon NS. Ovarian stimulation for in vitro fertilization alters the intrauterine cytokine, chemokine, and growth factor milieu encountered by the embryo. Fertil Steril. 2010;94(5):1764–8. https://doi.org/10.1016/j.fertnstert.2009.10.044.
10. Devroey P, Bourgaud C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004;15(2):84–90. https://doi.org/10.1016/j.tem.2004.01.009.
11. Dedhitt K, Fauser BC, Devroey P, Griesinger G. Eivan Annual Reproduction Workshop G. The role of the endometrium and embryo in human implantation. Hum Reprod Update. 2007;13(3):265–77. https://doi.org/10.1093/humupd/drm011.
12. Imudia AN, Awoyugba AO, Doyle JO, Kaimal AJ, Wright DL, Toth TL, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril. 2012;97(6):1374–9. https://doi.org/10.1016/j.fertnstert.2012.03.028.
13. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):634–79. https://doi.org/10.1016/j.fertnstert.2018.05.004.
14. Bonardi B, Massarotti C, Buzzone M, Goldratt O, Mangili G, Anserini P, et al. Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis. Front Oncol. 2020;10:74669. https://doi.org/10.3389/fonc.2020.0574669.
15. Haas J, Bassil R, Meriano J, Samara N, Barzilay E, Gonen N, et al. Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome? Reprod Biol Endocrinol. 2017;15(1):70. https://doi.org/10.1186/s12958-017-0288-8.
16. Goldratt O, Van Den Steen G, Gonzalez-Merino E, Dechene J, Gercy V, Delbaere A, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reprod Biol Endocrinol. 2019;17(1):13. https://doi.org/10.1186/s12958-018-0443-x.
17. Sonigo C, Sermondade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100049. https://doi.org/10.1016/j.eurox.2019.100049.

18. Hu YJ, Chen YZ, Zhu YM, Huang HF. Letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in women with polycystic ovarian syndrome: a pilot study. Clin Endocrinol (Oxf). 2014;80(2):283–9. https://doi.org/10.1111/cen.12280.

19. Li SJ, Zhang YJ, Chai XS, Nie MF, Zhou YY, Chen J, et al. Letrozole ovulation induction: an effective option in endometrial preparation for frozen-thawed embryo transfer. Arch Gynecol Obstet. 2014;289(3):687–93. https://doi.org/10.1007/s00404-013-3044-0.

20. Zhang J, Liu H, Wang Y, Mao X, Chen Q, Fan Y, et al. Letrozole use during frozen embryo transfer cycles in women with polycystic ovary syndrome. Fertil Steril. 2019;112(2):371–7. https://doi.org/10.1016/j.fertnstert.2019.04.014.

21. Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H. Pregnancy and neonatal outcomes following letrozole use in frozen-thawed single embryo transfer cycles. Hum Reprod. 2017;32(6):1244–8. https://doi.org/10.1093/humrep/dex066.

22. Zheng X, Guo W, Zeng L, Zheng D, Yang S, Wang L, et al. Live birth after in vitro maturation versus standard in vitro fertilisation for women with polycystic ovary syndrome: protocol for a non-inferiority randomised clinical trial. Bmj Open. 2020;10(4):e035334. https://doi.org/10.1136/bmjopen-2019-035334.

23. Zheng X, Guo W, Zeng L, Zheng D, Yang S, Xu Y, et al. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Hum Reprod. 2022;37(2):242–53. https://doi.org/10.1093/humrep/deab243.

24. Eftekhar M, Saeed L. Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: an RCT. Int J Reprod Biomed. 2020;18(4):287–94. https://doi.org/10.18502/ijrmv.134.6891.

25. Yang AM, Cui N, Sun YF, Hao GM. Letrozole for female infertility. Front Endocrinol (Lausanne). 2021;12:676133. https://doi.org/10.3389/fendo.2021.676133.

26. Shapira M, Orvieto R, Lebovitz O, Nahum R, Aizer A, Segev-Zahav A, et al. Does daily co-administration of gonadotropins and letrozole during the ovarian stimulation improve IVF outcome for poor and suboptimal responders? J Ovarian Res. 2020;13(1):66. https://doi.org/10.1186/s13048-020-00666-z.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.